Literature DB >> 34583417

Laboratory parameters between multisystem inflammatory syndrome in children and Kawasaki disease.

Chunling Zhou1, Yan Zhao1, Xia Wang2, Ying Huang3, Xuewen Tang4, Lei Tang1.   

Abstract

Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) has been described to partially overlap with Kawasaki disease (KD) with regard to clinical symptoms, but they are unlikely to share the same disease entity. We conducted a systematic review and meta-analysis to characterize the laboratory parameters of MIS-C compared with those of KD and Kawasaki disease shock syndrome (KDSS). Databases were searched for studies on laboratory parameters of MIS-C (hematology, inflammatory markers, cardiac markers, and biochemistry) through May 31, 2021. Twelve studies with 3073 participants yielded 969 MIS-C patients. In terms of hematology, MIS-C patients had lower levels of leukocytes, absolute lymphocyte count and platelet count (PLT) than KD patients and had similar absolute neutrophil count (ANC) and hemoglobin (Hb) levels. In terms of inflammatory markers, MIS-C patients had higher levels of C-reactive protein, D-dimer and ferritin than KD patients and had similar levels of procalcitonin and erythrocyte sedimentation rate (ESR). In terms of cardiac markers, MIS-C patients had higher CPK levels than KD patients. The levels of N-terminal pro-brain natriuretic peptide, troponin and aspartate aminotransferase were not significantly different between MIS-C and KD patients. In terms of biochemistry, MIS-C patients had lower levels of albumin, sodium and alanine aminotransferase and higher levels of creatinine than KD patients. In addition, MIS-C patients had lower levels of PLT, Hb and ESR and higher levels of ANC than KDSS patients. Measurement of laboratory parameters might assist clinicians with accurate evaluation of MIS-C and further mechanistic research.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; Kawasaki disease; Kawasaki disease shock syndrome; MIS-C; PIMS-TS; PMIS; SARS-CoV-2; children; laboratory parameters; meta-analysis

Mesh:

Year:  2021        PMID: 34583417     DOI: 10.1002/ppul.25687

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  3 in total

1.  Global Myocardial Strain in Multisystem Inflammatory Syndrome in Children, Kawasaki Disease, and Healthy Children: A Network Meta-Analysis.

Authors:  Kaiwei Liu; Jiahui Yu; Guang Song
Journal:  Front Pediatr       Date:  2022-06-27       Impact factor: 3.569

2.  Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child.

Authors:  Yohei Yamaguchi; Kei Takasawa; Hitoshi Irabu; Kanako Hiratoko; Yosuke Ichigi; Ko Hirata; Yumie Tamura; Miki Murakoshi; Motoi Yamashita; Hisae Nakatani; Masuhiro Shimoda; Taku Ishii; Tomohiro Udagawa; Masaki Shimizu; Hirokazu Kanegane; Tomohiro Morio
Journal:  J Infect Chemother       Date:  2022-01-24       Impact factor: 2.065

3.  The clinical implications of serum ferritin in Kawasaki disease: a helpful biomarker for evaluating therapeutic responsiveness, coronary artery involvement and the tendency of macrophage activation syndrome.

Authors:  Zhen Qiu; Hui Hui Liu; Guo Zhen Fan; Wei Xia Chen; Peng Hu
Journal:  Arch Med Sci       Date:  2021-12-08       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.